Showing results (141-150 of 177) with videos related to

Sort By:
Pageof 18
Clinical Genitourinary Cancer|January 29, 2023
A Phase 1/2 Study of Rapamycin and Cisplatin/Gemcitabine for Treatment of Patients With Muscle-Invasive Bladder CancerDimitrios Makrakis, Jonathan L Wright, Martine P Roudier, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 14, 2021
Phase II Multicenter Study of Enzalutamide in Metastatic Castration-Resistant Prostate Cancer to Identify Mechanisms Driving ResistanceRana R McKay, Lucia Kwak, Jett P Crowdis, et al.
Prostate Cancer and Prostatic Diseases|December 23, 2022
Bipolar androgen therapy plus olaparib in men with metastatic castration-resistant prostate cancerMichael T Schweizer, Roman Gulati, Todd Yezefski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 28, 2019
Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without AbirateroneRana R McKay, Huihui Ye, Wanling Xie, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2017
Association of Tissue Abiraterone Levels and <i>SLCO</i> Genotype with Intraprostatic Steroids and Pathologic Response in Men with High-Risk Localized Prostate CancerElahe A Mostaghel, Eunpi Cho, Ailin Zhang, et al.
Cancer Research|June 21, 2018
Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic AlterationsAdam G Sowalsky, Huihui Ye, Manoj Bhasin, et al.
Cell|June 16, 2018
Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate CancerYi-Mi Wu, Marcin Cieślik, Robert J Lonigro, et al.
The Prostate|September 13, 2021
Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutationsAlexandra O Sokolova, Catherine H Marshall, Rebeca Lozano, et al.
JCO Precision Oncology|May 25, 2019
Genomic Characterization of Prostatic Ductal Adenocarcinoma Identifies a High Prevalence of DNA Repair Gene MutationsMichael T Schweizer, Emmanuel S Antonarakis, Tarek A Bismar, et al.
European Urology Oncology|August 15, 2019
A Multicentre Analysis of the Detection of Clinically Significant Prostate Cancer Following Transperineal Image-fusion Targeted and Nontargeted Systematic Prostate Biopsy in Men at RiskSaiful Miah, Feargus Hosking-Jervis, Martin J Connor, et al.
Pageof 18